Preclinical studies have also documented synergistic interactions between pan-HDACi (i.e., vorinostat, SNDX-275, or SBHA) and the novel proteasome inhibitor carfilzomib (CFZ) in GCB- and ABC-DLBCL cells sensitive or resistant to bortezomib [560]. This evidence concerns the gene ABCB6 and diffuse large B-cell lymphoma.